title: Companies to pay $39.5m in OxyContin and Risperdal cases.
authors.affiliation: Seattle.
authors.forename: Michael
authors.initials: M
authors.lastname: McCarthy
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects*; D035881:Compensation and Redress / Q000331:legislation & jurisprudence*; D003257:Consumer Product Safety; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D006801:Humans; D016365:Liability, Legal; D009293:Opioid-Related Disorders / Q000453:epidemiology* / Q000517:prevention & control; D010098:Oxycodone / Q000008:administration & dosage / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing / Q000706:statistics & numerical data*; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects*; D014481:United States
chemical_list: D000701:Analgesics, Opioid; D018492:Dopamine Antagonists; D010098:Oxycodone; D018967:Risperidone